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Abstract
Aims The aim of this study is to investigate the effect of antidepressant therapy on mortality and cardiovascular outcomes in
patients with acute coronary syndrome (ACS).
Methods and results We systematically searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials
and performed a Bayesian random‐effects meta‐analysis of randomized controlled trials that investigated antidepressant phar-
macotherapy in patients following ACS. The primary outcome was all‐cause mortality. Secondary outcomes were repeat hos-
pitalizations and recurrent myocardial infarctions (MIs). Ten randomized controlled trials with a total of 1935 patients qualified
for inclusion. Selective serotonin reuptake inhibitors were investigated in six, bupropion in three, and mirtazapine in one trial.
Placebo was used as control in eight trials. There was no difference in all‐cause mortality [odds ratio (OR) 0.97, 95% credible
interval (CrI) 0.66–1.42] and recurrent MI (OR 0.64, 95% CrI 0.40–1.02) between patients receiving antidepressants compared
with controls, whereas antidepressant therapy was associated with less repeat hospitalizations (OR 0.62, 95% CrI 0.40–0.94).
In patients with ACS and concomitant depression, antidepressants reduced the odds of recurrent MI compared with usual
care/placebo (OR 0.45, 95% CrI 0.25–0.81). Extended funnel plots suggest robustness of the observations.
Conclusions Antidepressants in patients following ACS have no effect on mortality but reduce repeat hospitalizations; in pa-
tients with depression, there is a reduced risk of recurrent MI with antidepressant therapy.
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Introduction
Acute coronary syndromes (ACS) and major depressive disor-
ders are frequently intertwined and recognized to catalyze
the development and aggravate the clinical course of each
other.1,2 The prevalence of post‐myocardial infarction de-
pression is estimated to range between 10% and 40%, with
some reports describing clinical signs of depression in up to
two‐thirds of ACS survivors.3–6 Detection and treatment of
major depression in patients with cardiovascular disorders
has been demonstrated to improve therapy adherence, func-
tional ability, and quality of life.7–9 The optimal therapeutic
approach and the use, safety, and efficacy of antidepressant
pharmacotherapy in this population remain controversial,
however. Tricyclic antidepressants are well known for their
cardiovascular side effects. The newer selective serotonin
(SSRIs) and noradrenalin reuptake inhibitors are generally
considered safe in patients with cardiac co‐morbidities,10–12
although clinical and preclinical studies have shown that also
these drugs may interfere with myocardial ion channels, influ-
ence heart rate and blood pressure, and possibly exert
adverse effects by interacting with commonly used cardiac
medications, such as clopidogrel or beta‐blockers.12–17
Accordingly, ACS patients taking SSRIs were found to have
higher bleeding rates; moreover, an increased incidence of
sudden death in new generation antidepressant users has
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raised concerns about potential pro‐arrhythmic effects.15,18–
21 The objective of the present analysis was to summarize
the available evidence regarding the effects of antidepres-
sants on clinical outcomes in patients following ACS.
Methods
The study follows the Preferred Reporting Items for System-
atic Reviews and Meta‐Analyses statement22 and was pro-
spectively registered at the PROSPERO international register
of systematic reviews (CRD42018110818).
Search strategy and study selection
We systematically searched PubMed, Embase, and the
Cochrane Central Register of Controlled Trials from the date
of their inception up to 24 July 2019 for randomized
controlled trials (RCTs) that investigated the effect of one or
more pharmacological antidepressants compared with a
control (placebo or usual care) in patients following ACS with
respect to the outcomes of interest as described in the
succeeding text. The search algorithm applied to each
database is provided in Supporting Information, Table S1.
Following the initial search, we also scrutinized the reference
lists of eligible articles for additional relevant entries. To be
included, antidepressant treatment had to be initiated within
1 year after the index ACS and continued for a minimum of
30 days. ACS includes both ST‐elevation and non‐ST‐elevation
myocardial infarction and unstable angina pectoris. Studies
investigating patients with stable coronary artery disease
(CAD), chronic heart failure, and other cardiac or non‐cardiac
conditions were excluded. Also, non‐randomized studies,
studies without primarily pharmacological intervention and
without quantitative information on the outcomes of inter-
est, were excluded. Language was restricted to English or
German articles. In case of overlapping study populations
(according to participating institutions and recruitment
periods), we included the most recent results with the
longest available follow‐up and available data of interest.
Search results were screened on title and abstract level, and
potentially eligible reports were subsequently scrutinized in
full text according to the aforementioned inclusion criteria
by two investigators independently. In case of discrepancies
at either the screening or inclusion level, consensus was
found by common review and discussion between
investigators.
Data collection and outcomes of interest
For all eligible trials, we extracted the following items from
full‐text articles and any supplementary material into an
electronic data reporting form: study characteristics (first au-
thor, study title, study ID, year of publication, study design,
recruitment region and period of inclusion, sample size, arms
of randomization, and follow‐up duration); population char-
acteristics (age, sex, body mass index, smoking status,
co‐morbidities/past medical history, and left ventricular
ejection fraction); and characteristics of the interventions
(treatment arms, treatment initiation and duration, and drug
dosage).
The primary outcome was all‐cause mortality. Secondary out-
comes were myocardial infarction (MI) and rehospitalizations.
For all outcomes, the longest available follow‐up for each
individual trial was considered. We extracted the respective
numbers and percentages of events as well as applicable effect
sizes with respective adjustment factors.
Risk of bias
We used the Cochrane risk of bias tool23 to categorize the risk
of bias for each trial across the following domains: random
sequence generation, allocation concealment, blinding
(participants/personnel and outcomes), incomplete outcome
data, and selective outcome reporting. We evaluated the risk
of bias in each study as low, moderate, or high risk of bias,
based on our judgements for allocation concealment and
blinding of outcome assessment. A trial was considered to
be of low risk of bias, when both items were judged to be
low risk. When at least one of these two individual domains
was judged to be of unclear risk, we considered the random
sequence generation and incomplete outcome data domains.
A judgement of high risk of bias in one of these two domains
resulted in an overall high risk of bias; otherwise, the trial was
judged to be of moderate risk.
Sensitivity analyses
Sensitivity analyses were performed with regard to control
arm (trials in which placebo arm was tested), population
(ACS with or without concomitant depression), treatment ini-
tiation (after 30 days following the index cardiac event), and
treatment duration (>12 weeks).
Data synthesis and analysis
We synthesized the studies using a random‐effects meta‐
analysis model. Because of the limited number of the in-
cluded trials, meta‐analysis models were fitted in a Bayesian
framework. A Bayesian random‐effects meta‐analysis is
advantageous in such scenarios, because it incorporates
external evidence on the likely extent of between‐study het-
erogeneity in a particular research setting and facilitates
prediction of effects in future studies and flexibility in
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modelling.24–26 We presented the results by calculating the
odds ratio (OR) together with 95% credible intervals (CrIs).
We assumed a normal prior distribution with mean 0 and
standard deviation 1.52 for treatment effects [lower and
upper 95% limits (0.05, 20)]. We used informative priors
for heterogeneity, as derived from relevant empirical
distributions assuming an objective outcome for all‐cause
mortality and a semi‐objective outcome for recurrent MI
and rehospitalizations and a ‘pharmacological vs. placebo’ in-
tervention comparison type.27,28 The magnitude of the het-
erogeneity variance parameter (τ) was used to assess
statistically the presence of heterogeneity. To provide
useful additional information in decision‐making process,
we calculated the prediction intervals under the
Bayesian random‐effects meta‐analyses for each research
question.26,29,30 The prediction interval gives a range for the
predicted true effect size in an individual (future) trial of sim-
ilar setting.
We also investigated whether hypothetical future studies
are likely to alter the meta‐analysis results using extended
funnel plots.31 A colour code appended in conventional fun-
nel plots illustrates where the result of an updated
meta‐analysis would lie, depending on the effect estimate
and the standard error of a hypothetical new study to be
added to the evidence base. Heterogeneity was imputed to
equal the posterior value from the Bayesian meta‐analysis
(with the first prior), and contours of statistical significance
were drawn to represent a P‐value of 0.005.32,33 We consid-
ered a more conservative level of statistical significance
(0.5%) to avoid spuriously concluding over the benefit of
one of the two interventions. Statistical analyses were per-
formed using Stata 16.0 (StataCorp 2019, Stata Statistical
Software: Release 16, StataCorp LLC, College Station, TX)
and R (R Development Core Team, Vienna, Austria).
Results
Trial selection and characteristics
Our search yielded 2098 citations, from which 12 reports of
10 RCTs with a total of 1935 participants (68% male) fulfilled
our inclusion criteria (Figure 1). A few landmark trials in the
field were excluded because of ineligible comparisons, study
populations, and/or outcomes as provided in Supporting In-
formation, Table S2 together with the reasons for exclusion.
Characteristics of included trials and enrolled participants
are summarized in in Tables 1 and 2. Six trials (eight
reports)8,9,34–37,42,43 included patients with ACS and a con-
comitant diagnosis of depression, one trial40 was performed
in patients with ACS without depression, and three
trials38,39,41 investigated the use of bupropion for smoking
cessation after ACS. Other tested drugs apart from bupropion
were SSRIs in six9,34–37,40,42,43 and the noradrenergic and spe-
cific serotonergic antidepressant mirtazapine in one RCT.8 In
four trials, antidepressant pharmacotherapy was initiated
in‐hospital up to 1 month after the index cardiac
event,38,39,41,42 whereas in the other five trials, drug therapy
was started up to 12 months thereafter8,9,34–36,40,43; in one
trial, the timing of antidepressant initiation was not
reported.37 Treatment duration ranged from 8 to 52 weeks.
The median follow‐up time was 12 months with a range from
2 months to 8 years (Table 1).
Primary outcome
Six trials involving 1572 patients provided adequate data on
all‐cause mortality.9,35–38,40,41,43 During a median follow‐up
period of 12 months, 171 events were reported. The
summary effect estimate showed no difference between
patients receiving antidepressant pharmacotherapy com-
pared with those under placebo/usual care (OR 0.97, 95%
CrI 0.66–1.42), with low heterogeneity across the trials
(τ ¼ 0.12, prediction interval OR 0.97, 95% CrI 0.58–1.63,
Figure 2A). Also, sensitivity analyses considering only trials
with placebo control, trials in patients with major depression
and ACS, treatment initiation after 30 days, and treatment
duration beyond 12 weeks revealed no differences between
groups (Supporting Information, Figures S1A–S4A).
Secondary outcomes
Data on recurrent MI were available in seven trials with a to-
tal of 1536 randomized patients and 98 events during a
median follow‐up period of 12 months.9,35–37,39–43 As shown
in Figure 2B, there was no difference between the treatment
arms (OR 0.64, 95% CrI 0.40–1.02) in the main analysis
neither in the sensitivity analyses based on type of
control arm, treatment initiation, and treatment duration
(Supporting Information, Figures S1B, S3B, and S4B, respec-
tively). Restricting the analysis to trials enrolling patients with
ACS and a concomitant diagnosis of depression,8,9,34–37,41–43
antidepressant therapy was associated with reduction in odds
of recurrent MI compared with usual care/placebo (OR 0.45,
95% CrI 0.25–0.81), with a 95% prediction interval of
0.21–0.97 (Supporting Information, Figure S2B).
Repeat hospitalizations were assessed in five trials
including 682 participants and 220 events during a median
follow‐up period of 12 months.8,9,34–37,39 Antidepressants
decreased the odds of the participants having repeat
hospitalizations compared with placebo/usual care (OR 0.62,
95% CrI 0.40–0.94) (95% prediction interval of 0.33–1.13)
(Figure 2C). The results were consistent also in sensitivity
analyses (Supporting Information, Figures S1C–S4C).
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Extended funnel plots
Figure 3 shows extended funnel plots for all outcomes.
Shaded regions depict where the effect size/standard error
combination of a hypothetical novel study must lie in order
to alter the conclusion of the present analysis in favour of
treatment (medium grey) or placebo/usual care (dark grey).
Extended funnel plots point towards robustness of the cur-
rent analysis as any additional trial of similar effect
size/standard error combination in the range of existing trials
will not considerably alter the results.
Risk of bias
Results of the risk of bias assessment are summarized in
Figure 4. The overall risk of bias was deemed low, intermedi-
ate, and high in four, two, and four trials, respectively, al-
though insufficient reporting resulted in many domains
being rated as unclear risk of bias. Incomplete outcome
reporting was the domain with the highest risk of bias, as half
of the included trials suffered from high rates of follow‐up
losses.
Discussion
In this systematic review and meta‐analysis of 10 RCTs com-
paring antidepressants to placebo/usual care in patients fol-
lowing ACS, we found no difference in mortality, while
antidepressant therapy reduced the risk of repeat hospitaliza-
tions. In patients with concomitant depression, antidepres-
sants additionally decreased the odds of patients having
recurrent MIs compared with placebo/usual care.
Approximately one in eight patients with an ACS takes an
antidepressant agent.10,44,45 The efficacy of antidepressants
to ameliorate depression and functional scores is well
established, whereas their impact on cardiovascular out-
comes remains a topic of ongoing discussion.16,17,46 In a
meta‐analysis on the effect of SSRIs in patients with acute
or stable CAD, Mazza and colleagues found that the
Figure 1 Preferred Reporting Items for Systematic Reviews and Meta‐Analyses flow diagram of literature search and study selection. FU, follow‐up.
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treatment lowered readmission rates without affecting major
cardiovascular adverse events, MIs, repeat revascularizations
or mortality.10 Our study differs from the former by the ex-
clusive inclusion of patients with ACS. Moreover, we consid-
ered also non‐SSRI antidepressants and identified eight
additional studies that were not included in the previous
meta‐analysis that was published nearly 10 years ago.8,36,38–
43 While the findings of our updated meta‐analysis are largely
consistent with the study by Mazza and colleagues, we found
a lower rate of recurrent MIs in ACS patients with major de-
pression under treatment with antidepressants. Another
meta‐analysis on the impact of SSRIs in patients recovering
from interventions for stable or acute CAD was performed
by Pizzi and colleagues.11 The authors considered both ran-
domized trials (three of which were included also in our
analysis34,37,43) as well as non‐randomized studies. Consistent
with the findings of Mazza and colleagues and our study, the
authors reported a reduction of rehospitalizations by SSRI
treatment in patients with CAD and major depression. Addi-
tionally, Pizzi and colleagues found that SSRI treatment re-
duced mortality rates, which was mainly driven by the
inclusion of a post hoc analysis of the ENRICHD trial that
showed that depressed and/or socially isolated patients with
recent ACS taking SSRIs had a significantly lower risk of recur-
rent MI and all‐cause mortality over a mean follow‐up period
of 29 months compared with controls.47 In our study, in
which only RCTs were included, we found no difference in
mortality rates between active treatment and control arms.
Nevertheless, our results strengthen the accumulating evi-
dence that antidepressant therapy might have a favourable
Figure 2 Forest plot of the primary and secondary endpoints. The figure shows the results of Bayesian random‐effects meta‐analysis of antidepressant
therapy vs. placebo/usual care on (A) all‐cause mortality, (B) recurrent myocardial infarction (MI), and (C) rehospitalization. CrI, credible interval; OR,
odds ratio.
6 R. Sweda et al.
ESC Heart Failure (2020)
DOI: 10.1002/ehf2.12861
risk/benefit ratio in CAD patients with major depression and
suggest a proactive approach in this population, although
the optimal strategy to identify and deal with the
unfavourable combination of depression and CAD remains
to be determined.48
The mechanisms by which depression negatively affects
the cardiovascular system and by which therapeutic inter-
ventions exert positive effects are not well understood. Hy-
potheses for an adverse impact of depression include a
dysregulation of autonomic control, up‐regulation of
pro‐inflammatory molecules, and increased platelet activa-
tion in depressed patients.49–52 Pharmacological antidepres-
sant therapy on the other hand has been demonstrated to
reduce systemic sympathetic nervous activity, improve ther-
apy adherence, and encourage health behaviours.49–52 Our
finding that antidepressants reduce the rate of recurrent
MIs in patients with major depression but not in the overall
population supports these concepts. Another particularly in-
triguing observation is the recently described inhibitory ef-
fect of the SSRI paroxetine on the G protein‐coupled
receptor kinase GRK2, which plays a major role in the de-
velopment of cardiovascular disease.53–55 Inhibition of the
protein in various preclinical studies was shown to improve
myocardial contractility, reverse cardiac remodelling, and
attenuate heart failure progression.55–58 Whether these
preclinical observations translate into a measurable effect
in humans remains to be determined. From the trials in-
cluded in this meta‐analysis, only one specifically investi-
gated paroxetine.42 In this study, Tian and colleagues
found that GRK2 expression was higher in patients with
ACS and concomitant depression and that paroxetine treat-
ment reduced the levels of GRK2, led to a normalization of
the autonomic nervous system function, improved
cardiac performance, and lowered the rate of recurrent
infarctions42. Potentially beneficial effects of paroxetine in
patients with ACS irrespective of depression are currently
being tested in a double‐blinded RCT (NCT03274752), which
will hopefully shed further light on the therapeutic poten-
tial of this drug for reversal of the adverse sequelae follow-
ing myocardial ischaemia.
Limitations
The results of our analysis have to be interpreted in view of
several limitations. First, we did not have any access to
patient‐level data, and all analyses were performed on a pop-
ulation level, with insufficient data to identify potentially rel-
evant subgroups. Second, although we identified 10 eligible
trials, the cumulative number of participants and events
was low. In specific, for the primary outcome of all‐cause
mortality, the majority of events occurred within two trials,
while the others contributed only little to the derived esti-
mate. Third, the included trials varied in a number of relevant
characteristics. Apart from differences in eligible populations
(including both depressed and not depressed patients), treat-
ment regimens, and follow‐up durations, also the inclusion
Figure 3 Extended funnel plots for all outcomes. The funnel plots show
the conclusions of an updated meta‐analysis including a hypothetical
new trial with certain combinations of treatment effect (odds ratio) and
standard error. Solid line represents the line of no effect, and the dotted
line represents the summary odds ratio. Dots indicate the odds ratio and
the standard error of the existing studies. An updated meta‐analysis in-
cluding a new study lying in the light grey area will remain
non‐statistically significant; an updated meta‐analysis including a new
study lying in the dark grey area will become statistically significant
favouring usual care; an updated meta‐analysis including a new study ly-
ing in the medium grey area will become statistically significant favouring
experimental. Statistical significance was judged on the 0.005 level. (A)
All‐cause mortality, (B) recurrent myocardial infarction, and (C)
rehospitalization.
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period extends over a long time span during which standards
of care have changed. Especially on the cardiological side,
both interventional and post‐interventional therapies have
experienced a remarkable evolution over the last decade,
which is important to keep in mind with regard to potential
drug interactions as a driving factor of adverse events. Even
though we observed no signal for the overall treatment strat-
egy, we cannot exclude relevant effects for individual agents.
Conversely, higher adverse event rates due to side effects are
expected to occur around the time of drug ingestion,
whereas beneficial effects may take years to become
apparent. Consistent with this, the recently reported
long‐term results of the double‐blind randomized EsDEPACS
trial showed that patients with post‐ACS depression that
were allocated to a 24 week treatment with escitalopram
had a significantly lower rate of major adverse cardiac events
compared with the placebo arm after 8 years of follow‐up,
while this was not observed at an earlier time point.43,59 In
our analysis, the median follow‐up duration was 1 year, and
only three of the 10 trials reported long‐term outcomes. Fi-
nally, patients recruited in RCTs are well selected and might
not represent the general population. However, we decided
Figure 4 Risk of bias for each study (A) and for each item presented as percentage across all included studies (B).
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not to include non‐randomized studies of similar interven-
tions, because multiple sources of biases could not have been
accounted for in our analysis.
Conclusions
Current evidence suggests that antideprssants in patients
following ACS have no effect on mortality but reduce re-
peat hospitalizations; in patients with depression, there is
a reduced risk of recurrent MI with antidepressant therapy.
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Figure S1. Forest plot showing the results of Bayesian
random‐effects meta‐analysis of antidepressant therapy vs.
placebo on all‐cause mortality (A), recurrent myocardial in-
farction (B) and rehospitalization (C) including only trials with
placebo arm.
Figure S2. Forest plot showing the results of Bayesian
random‐effects meta‐analysis of antidepressant therapy vs.
placebo/usual care on all‐cause mortality (A), recurrent myo-
cardial infarction (B) and rehospitalization (C) including only
trials with patients diagnosed with ACS and depression.
Figure S3. Forest plot showing the results of Bayesian
random‐effects meta‐analysis of antidepressant therapy vs.
placebo/usual care on all‐cause mortality (A), recurrent myo-
cardial infarction (B) and rehospitalization (C) including only
trials with antidepressant treatment initiation after the first
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Figure S4. Forest plot showing the results of Bayesian
random‐effects meta‐analysis of antidepressant therapy vs.
placebo/usual care on all‐cause mortality (A), recurrent
myocardial infarction (B) and rehospitalization (C) including
only trials with treatment duration of more than 12 weeks.
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